$BIORQ
BIORA THERAPEUTICS, INC.

2024 Q3 Form 10-Q Financial Statement

#000095017024095491 Filed on August 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $32.00K $318.0K
YoY Change 15800.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.65M $8.400M
YoY Change -16.64% -6.18%
% of Gross Profit
Research & Development $5.610M $7.704M
YoY Change -46.81% 28.76%
% of Gross Profit
Depreciation & Amortization $100.0K $100.0K
YoY Change 0.0% -50.0%
% of Gross Profit
Operating Expenses $16.26M $16.10M
YoY Change -30.28% 7.82%
Operating Profit -$16.23M -$15.79M
YoY Change -30.42% 5.71%
Interest Expense $2.016M $711.0K
YoY Change -22.22% -73.7%
% of Operating Profit
Other Income/Expense, Net -$12.28M $9.892M
YoY Change -76.44% -197940.0%
Pretax Income -$22.26M $6.398M
YoY Change -69.69% -135.94%
Income Tax -$44.00K -$67.00K
% Of Pretax Income -1.05%
Net Earnings -$18.40M $6.465M
YoY Change -74.95% -136.31%
Net Earnings / Revenue -57506.25% 2033.02%
Basic Earnings Per Share -$5.04 $0.18
Diluted Earnings Per Share -$5.04 -$0.04
COMMON SHARES
Basic Shares Outstanding 36.47M 35.88M
Diluted Shares Outstanding 3.653M 74.22M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.196M $5.325M
YoY Change -74.63% -79.87%
Cash & Equivalents $3.000M $5.100M
Short-Term Investments
Other Short-Term Assets $45.00K $406.0K
YoY Change -73.84% 110.36%
Inventory
Prepaid Expenses $1.945M $2.648M
Receivables
Other Receivables
Total Short-Term Assets $6.054M $9.201M
YoY Change -68.55% -72.85%
LONG-TERM ASSETS
Property, Plant & Equipment $1.175M $1.268M
YoY Change -4.94% -6.14%
Goodwill $6.072M $6.072M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Other Assets $193.0K $505.0K
YoY Change -96.94% -92.2%
Total Long-Term Assets $8.451M $9.062M
YoY Change -45.32% -42.6%
TOTAL ASSETS
Total Short-Term Assets $6.054M $9.201M
Total Long-Term Assets $8.451M $9.062M
Total Assets $14.51M $18.26M
YoY Change -58.2% -63.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.916M $7.512M
YoY Change 77.11% 48.99%
Accrued Expenses $21.31M $15.58M
YoY Change 1.0% -26.77%
Deferred Revenue $0.00 $32.00K
YoY Change -100.0% -23.81%
Short-Term Debt $4.527M $0.00
YoY Change
Long-Term Debt Due $34.07M $1.912M
YoY Change
Total Short-Term Liabilities $120.6M $45.99M
YoY Change 73.44% 22.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $43.77M
YoY Change -100.0% -65.96%
Other Long-Term Liabilities $516.0K $581.0K
YoY Change -85.53% -86.54%
Total Long-Term Liabilities $516.0K $581.0K
YoY Change -85.53% -86.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $120.6M $45.99M
Total Long-Term Liabilities $516.0K $581.0K
Total Liabilities $121.1M $107.6M
YoY Change -21.08% -36.92%
SHAREHOLDERS EQUITY
Retained Earnings -$967.1M -$948.7M
YoY Change 3.38% 10.05%
Common Stock $879.5M $878.4M
YoY Change 5.23% 15.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$106.6M -$89.32M
YoY Change
Total Liabilities & Shareholders Equity $14.51M $18.26M
YoY Change -58.2% -63.23%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$18.40M $6.465M
YoY Change -74.95% -136.31%
Depreciation, Depletion And Amortization $100.0K $100.0K
YoY Change 0.0% -50.0%
Cash From Operating Activities -$8.730M -$10.95M
YoY Change -20.85% -5.76%
INVESTING ACTIVITIES
Capital Expenditures $19.00K $180.0K
YoY Change 800.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$19.00K -$180.0K
YoY Change 847.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.620M 5.637M
YoY Change -332.28% -26.12%
NET CHANGE
Cash From Operating Activities -8.730M -10.95M
Cash From Investing Activities -19.00K -180.0K
Cash From Financing Activities 6.620M 5.637M
Net Change In Cash -2.129M -5.495M
YoY Change -84.66% 37.0%
FREE CASH FLOW
Cash From Operating Activities -$8.730M -$10.95M
Capital Expenditures $19.00K $180.0K
Free Cash Flow -$8.749M -$11.13M
YoY Change -20.68% -4.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001580063
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://bioratherapeutics.com/20240630#AccruedExpensesAndOtherLiabilitiesCurrent
us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2024-04-01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39334
dei Entity Registrant Name
EntityRegistrantName
Biora Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3950390
dei Entity Address Address Line1
EntityAddressAddressLine1
4330 La Jolla Village Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92122
dei City Area Code
CityAreaCode
833
dei Local Phone Number
LocalPhoneNumber
727-2841
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
BIOR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36469088
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5325000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15211000
CY2024Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
822000
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
830000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3054000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3030000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
9201000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19071000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1268000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1156000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1217000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1614000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
505000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3302000
CY2024Q2 us-gaap Goodwill
Goodwill
6072000
CY2023Q4 us-gaap Goodwill
Goodwill
6072000
CY2024Q2 us-gaap Assets
Assets
18263000
CY2023Q4 us-gaap Assets
Assets
31215000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
7512000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2843000
CY2024Q2 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
19568000
CY2023Q4 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
17319000
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
17001000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
40834000
CY2024Q2 bior Related Party Senior Secured Convertible Notes Current
RelatedPartySeniorSecuredConvertibleNotesCurrent
1912000
CY2023Q4 bior Related Party Senior Secured Convertible Notes Current
RelatedPartySeniorSecuredConvertibleNotesCurrent
1976000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
45993000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62972000
CY2024Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4512000
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
9966000
CY2024Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
19842000
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
14591000
CY2024Q2 bior Related Party Senior Secured Convertible Notes Non Current
RelatedPartySeniorSecuredConvertibleNotesNonCurrent
19411000
CY2023Q4 bior Related Party Senior Secured Convertible Notes Non Current
RelatedPartySeniorSecuredConvertibleNotesNonCurrent
19179000
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
17246000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
22899000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
581000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3029000
CY2024Q2 us-gaap Liabilities
Liabilities
107585000
CY2023Q4 us-gaap Liabilities
Liabilities
132636000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
164000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36689240
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28574918
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35943235
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27837563
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
34000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
25000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
878405000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
868591000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-948682000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-950958000
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
746005
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
737355
CY2024Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
19079000
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
19079000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-89322000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-101421000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18263000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31215000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
318000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
860000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7704000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5983000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14709000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13173000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8400000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8953000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17453000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17309000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
16104000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
14936000
us-gaap Operating Expenses
OperatingExpenses
32162000
us-gaap Operating Expenses
OperatingExpenses
30482000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15786000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14934000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31302000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30478000
CY2024Q2 us-gaap Interest Expense
InterestExpense
711000
CY2023Q2 us-gaap Interest Expense
InterestExpense
2703000
us-gaap Interest Expense
InterestExpense
3468000
us-gaap Interest Expense
InterestExpense
5383000
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-13003000
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
161000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-26918000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-703000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9892000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10109000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-86000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6398000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17803000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2257000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35244000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-67000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-19000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
6465000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17807000
us-gaap Net Income Loss
NetIncomeLoss
2276000
us-gaap Net Income Loss
NetIncomeLoss
-35248000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.01
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.01
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35720168
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12143108
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32508467
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11718408
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74215969
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12143108
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69282114
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11718408
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-101421000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2824000
CY2024Q1 bior Stock Issued During Period Value Purchase Warrants
StockIssuedDuringPeriodValuePurchaseWarrants
1062000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1539000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-4189000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-100185000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2807000
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-6000
CY2024Q2 bior Stock Issued During Period Value Purchase Warrants
StockIssuedDuringPeriodValuePurchaseWarrants
24000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1573000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-89322000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-102287000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12524000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-178000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2384000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17441000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-104998000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-90000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2014000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17807000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-120881000
us-gaap Net Income Loss
NetIncomeLoss
2276000
us-gaap Net Income Loss
NetIncomeLoss
-35248000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
215000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
313000
us-gaap Share Based Compensation
ShareBasedCompensation
3112000
us-gaap Share Based Compensation
ShareBasedCompensation
4398000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-185000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2279000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
757000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-10000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-9000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
100000
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-10252000
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-26918000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-703000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-8000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-10000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
226000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
59000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4177000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1437000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2113000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6170000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-427000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-904000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23448000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23720000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
195000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
20000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
11000
us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
3000000
us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2825000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6102000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12883000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
2819000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
8000000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2813000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
384000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
484000
bior Payments For Insurance Financing
PaymentsForInsuranceFinancing
607000
bior Payments For Insurance Financing
PaymentsForInsuranceFinancing
688000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
6000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10737000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19711000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9886000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4034000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15211000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30486000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5325000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26452000
us-gaap Interest Paid Net
InterestPaidNet
244000
us-gaap Interest Paid Net
InterestPaidNet
1059000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
61000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
11000
bior Exchange Of Convertible Notes For Senior Secured Convertible Notes And Warrants
ExchangeOfConvertibleNotesForSeniorSecuredConvertibleNotesAndWarrants
5625000
bior Exchange Of Convertible Notes For Senior Secured Convertible Notes And Warrants
ExchangeOfConvertibleNotesForSeniorSecuredConvertibleNotesAndWarrants
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1133000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
402000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
161000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5100000
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
200000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-948700000
us-gaap Net Income Loss
NetIncomeLoss
2300000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include the valuation of stock options, the valuation of goodwill, the valuation of the derivative liabilities associated with the 2028 Convertible Notes, accrual for reimbursement claims and settlements, the valuation of warrant liabilities, assessing future tax exposure and the realization of deferred tax assets, and the useful lives and the recoverability of property and equipment. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></p>
CY2024Q2 bior Restricted Cash Collateral For Credit Cards
RestrictedCashCollateralForCreditCards
200000
CY2023Q4 bior Restricted Cash Collateral For Credit Cards
RestrictedCashCollateralForCreditCards
200000
CY2023Q4 us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
2800000
CY2023Q4 bior Cost Incurred In Sale Of Property Plant And Equipment
CostIncurredInSaleOfPropertyPlantAndEquipment
200000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2648000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2443000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
406000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
587000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3054000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3030000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3561000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3263000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2293000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2107000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1268000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1156000
CY2024Q2 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
200000
CY2023Q2 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
300000
CY2024Q2 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
505000
CY2023Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
302000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
505000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3302000
CY2024Q2 bior Accrual For Reimbursement Claims And Settlements Current
AccrualForReimbursementClaimsAndSettlementsCurrent
3572000
CY2023Q4 bior Accrual For Reimbursement Claims And Settlements Current
AccrualForReimbursementClaimsAndSettlementsCurrent
6337000
CY2024Q2 bior Commission And Bonus Current
CommissionAndBonusCurrent
2887000
CY2023Q4 bior Commission And Bonus Current
CommissionAndBonusCurrent
2469000
CY2024Q2 bior Vacation And Payroll Benefits Current
VacationAndPayrollBenefitsCurrent
1485000
CY2023Q4 bior Vacation And Payroll Benefits Current
VacationAndPayrollBenefitsCurrent
1367000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4721000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2914000
CY2024Q2 bior Accrued Interest Current
AccruedInterestCurrent
347000
CY2023Q4 bior Accrued Interest Current
AccruedInterestCurrent
173000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
882000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
896000
CY2024Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1683000
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
401000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
32000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
542000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3959000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2220000
CY2024Q2 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
19568000
CY2023Q4 bior Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
17319000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
402000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
818000
CY2024Q2 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
179000
CY2023Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
2211000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
581000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3029000
CY2024Q2 bior Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q2 bior Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2024Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
19842000
CY2024Q2 bior Related Party Senior Secured Convertible Notes
RelatedPartySeniorSecuredConvertibleNotes
21323000
CY2024Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4512000
CY2023Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
14591000
CY2023Q4 bior Related Party Senior Secured Convertible Notes
RelatedPartySeniorSecuredConvertibleNotes
21155000
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
9966000
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
50000000
bior Class Of Warrant Or Right Period For Warrants Or Rights Exercisable
ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable
after September 18, 2023 until September 18, 2026
CY2023Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
53200000
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
35100000
CY2023 us-gaap Gains Losses On Restructuring Of Debt
GainsLossesOnRestructuringOfDebt
25500000
CY2023 bior Troubled Debt Restructuring Debtor Future Interest Payments Capitalized
TroubledDebtRestructuringDebtorFutureInterestPaymentsCapitalized
11700000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
800000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
235000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
409000
us-gaap Operating Lease Cost
OperatingLeaseCost
470000
us-gaap Operating Lease Cost
OperatingLeaseCost
793000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
518000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
590000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
264000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
18000
CY2024Q2 bior Lessee Operating Lease Liability Payments Due Year After
LesseeOperatingLeaseLiabilityPaymentsDueYearAfter
0
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1390000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
106000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1284000
CY2020Q3 bior Number Of States Participating In Settlement
NumberOfStatesParticipatingInSettlement
45
us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
0
us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
2800000
CY2020Q4 bior Number Of Actions Pending
NumberOfActionsPending
2
CY2020Q4 bior Number Of Actions Pending
NumberOfActionsPending
2
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
1000000
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On January 3, 2023, the Company effected the Reverse Stock Split of the Company's common stock.
CY2023Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
5.3
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3018868
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.05
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7300000
CY2023Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
8000000
CY2023Q2 bior Gain Loss On Warrant Liability
GainLossOnWarrantLiability
1000000
CY2023Q2 bior Warrants And Common Stock Issuance Cost
WarrantsAndCommonStockIssuanceCost
700000
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1000000
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
4278074
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.93
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.87
CY2023Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
9900000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6700000
CY2023Q4 bior Gain Loss On Warrant Liability
GainLossOnWarrantLiability
6700000
CY2024Q1 bior Gain Loss On Warrant Liability
GainLossOnWarrantLiability
1500000
CY2024Q2 bior Proceeds From Issuance Of Shares And Warrants
ProceedsFromIssuanceOfSharesAndWarrants
5500000
CY2024Q1 bior Warrants And Common Stock Issuance Cost
WarrantsAndCommonStockIssuanceCost
700000
CY2024Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
56632589
CY2022Q4 bior Number Of Vote Per Preferred Stock Held
NumberOfVotePerPreferredStockHeld
3000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
763012
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
36.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
78800
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.71
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7671
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
59.68
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
834141
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
834141
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
32.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
402784
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
50.45
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.043
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.047
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.968
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.013
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.027
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.59
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.93
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1573000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2014000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3112000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4398000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2024Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
6465000
us-gaap Net Income Loss
NetIncomeLoss
2276000
CY2024Q2 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
740000
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
3533000
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-9834000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-10252000
CY2024Q2 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-2629000
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-4443000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35720168
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32508467
CY2024Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
38495801
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
36773647
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74215969
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69282114
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
55202486
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8804945
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
52515183
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8804945
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 bior Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q2 bior Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-095491-index-headers.html Edgar Link pending
0000950170-24-095491-index.html Edgar Link pending
0000950170-24-095491.txt Edgar Link pending
0000950170-24-095491-xbrl.zip Edgar Link pending
bior-20240630.htm Edgar Link pending
bior-20240630.xsd Edgar Link pending
bior-ex31_1.htm Edgar Link pending
bior-ex31_2.htm Edgar Link pending
bior-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
bior-20240630_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable